Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2089 08/10/2018 gemtuzumab ozogamicin (Mylotarg) Full Combination therapy with daunorubicin and cytarabine (DA) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive AML, except acute promyelocytic leukaemia (APL).

No medicines have been found.